<unk>  was approved by the U.S. Food and Drug Administration (FDA) in June 2003, to treat adults with Parkinson's disease of unknown cause in two scenarios. First, to substitute with equivalent strength of each of the three components for immediate-release<unk><unk>  and<unk>  previously administered as individual products. Second, to replace immediate-release<unk><unk>  therapy (without<unk>  when people experience the signs and symptoms of end-of-dose "wearing-off" but only for people taking a total daily dose of<unk>  of 600 mg or less and not experiencing dyskinesias. It may help decrease a change of response to Parkinson's medications. In the European Union it is indicated for the treatment of adults with Parkinson's disease and end-of-dose motor fluctuations not stabilized on<unk> /dopa decarboxylase (DDC) inhibitor treatment.
Carbidopa/levodopa/entacapone
Fluorodopa
Bromperidol decanoate
Donepezil
3-Quinuclidinyl benzilate
Protriptyline
Perhexiline
Rivastigmine